Monday, November 28, 2011

Gilead wins European approval of HIV combo treatment

Gilead Sciences Inc. won European approval of a once-a-day tablet for HIV patients.
The drug, Eviplera, combines Gilead-developed Truvada — which itself is a combination of emtricitabine and tenofovir — and Tibotec Pharmaceuticals’ Edurant.
European approval allows the drug to be marketed in all 27 European Union countries to fight HIV-1 infection in adults with 100,000 copies or less per milliliter of blood and who have not previously been treated with antiretroviral drugs.

No comments:

Post a Comment

Post a Comment